Role of Tumor Microenvironment in the Risk of Thromboembolic Complications in Ovarian Cancer

Introduction. Incidence of ovarian cancer remains high in the overall prevalence of oncological pathology. Adjuvant chemotherapy refers to its treatment options. Patients with oncological pathology are faced with a high risk of thrombosis and thromboembolism, with up to 30% lethal outcome within a month of its development. A number of cancer cells are known to induce platelet aggregation, contributing to thrombosis and metastasis as a result of this interaction. Accordingly, the paper is aimed at presenting a clinical case for demonstrating the role of P-selectin expression in the complications in a patient with ovarian cancer. Materials and methods. The present paper evaluates platelet activation marker in a patient undergoing chemotherapy courses after cytoreductive surgery. Following the case conference and in accordance with the clinical recommendations of the Russian Oncology Association (AOR) and Russian Society of Clinical Oncology (RUSSCO), cytoreduction (CC-0), radical hysterectomy, transverse colectomy, left hemicolectomy with rectum resection were performed. The interventions included ascendostomy, pelvic, lateral right-sided and left-sided peritonectomy, pelvic lymphoadenectomy, total omentectomy, Renape-French HIPEC (hyperthermic intraperitoneal chemotherapy), abdominal and pelvic drainage. Expression of P-selectin on the platelet surface was measured as a marker of platelet activation. Results and discussion. At the time of admission, the patient had high CD62 expression activity compared to healthy volunteers (CD62 ADP^- — 11.2%, CD62 ADP — 24.7% vs CD62 ADP^- — 1.3%, CD62 ADP — 17.2%). During the complex treatment of ovarian cancer, the platelet activation increased (CD62 ADP^- — 21.8 %, CD62 ADP⁺ — 30.1 %). At discharge, CD62 expression values reached the conditional norm, presumably indicating thrombosis development. Conclusion. Tumor microenvironment influences the hemostasis system. Detailed study into this issue obtains a high potential for the prevention of primary and secondary thromboembolic complications in oncologic patients.

1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.). The status of cancer care for the population of Russia in 2022. Moscow: National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2023. 242 p. (In Russ.)

2. Savinova A.R., Gataullin I.G. Personalized approach to the ovarian cancer treatment // Kazan medical journal. 2016;97(3):388–93 (In Russ.). DOI: 10.17750/KMJ2016-388

3. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. DOI: 10.1016/S0140-6736(17)32154-2

4. Global Burden of Disease Study Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88. DOI: 10.1016/S0140-6736(18)32203-7

5. Tyulyandina A.S., Kolomiets L.А., Morkhov K.Yu, Nechushkina V.M., Pokataev I.А., Rumyantsev I.A. Practical recommendations for the drug treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Malignant tumors. 2021;11(3s2-1):158–71 (In Russ.). DOI: 10.18027/2224-5057-2021-11-3s2-10

6. Chua T.C., Yan T.D., Saxena A., Morris D.L. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2019;249(6):900–7. DOI: 10.1097/sla.0b013e318 1a45d86

7. Reuss А., du Bois А., Harter Р. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327–31. DOI: 10.1136/ijgc-2019-000682

8. van Driel W.J., Koole S. N., Sikorska K. Hyperthermic intraperitoneal chemotherapy in ovarian cancer.

9. Ji Z.H., Yu Y., Liu G., Zhang Y.B., An S.L., Li B., et al. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Eur J Surg Oncol. 2021;47(6):1411–9. DOI: 10.1016/j.ejso.2020.11.139

10. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020;30(6):888–92. DOI: 10.1136/ijgc-2020-001231

11. Ntatsis K., Papantoni E., Kyziridis D., Kalakonas A., Hristakis C., Tzavara C., et al. Ovarian cancer: 20-year experience with cytoreductive surgery and perioperative intraperitoneal chemotherapy. J BUON. 2021;26(5):1754–61. PMID: 34761579

12. Swier N., Versteeg H.H. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Thrombosis Research. 2017;150:8–18. DOI: 10.1016/j.thromres.2016.12.002

13. Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017;31(3):387–401. DOI: 10.1016/j.bpa.2017.08.005

14. Sugarbaker P.H., Stuart O.A. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. Surg Oncol. 2020;33:96–9. DOI: 10.1016/j.suronc.2020.01.009

15. European School of Peritoneal Surface Oncology (ESPSO) [cited 2020 Dec 20]. Available from:www.essoweb.org/school-of-peritonealsurfaceoncology-es

16. Urakov A.L., Samorodov A.V., Kamilov F.Kh., Mustafin I.G., Khaliullin F.A. P-selectin expression of and platelet aggregation under the action of drugs. Pharmacy. 2017;66(3):43–6 (In Russ.).

17. Kamilov F.K., Timirkhanova G.A., Samorodov A.V., Khaliullin F.A. Choosing potential dissolution medium to study the influence of waterinsoluble substances on aggregation of platelets within preclinical studies under conditions in vitro. Biology and Medicine. 2013;5(1):15–9.

18. McNamee N., de la Fuente L.R., Santos-Martinez M.J., O’Driscoll L. Proteomics profiling identifies extracellular vesicles’ cargo associated with tumour cell induced platelet aggregation. BMC Cancer. 2022;22(1):1023. DOI: 10.1186/s12885-022-10068-7

19. Schwarz S., Gockel L.M., Naggi A., Barash U., Gobec M., Bendas G., et al. Glycosaminoglycans as tools to decipher the platelet tumor cell interaction: a focus on P-selectin. Molecules. 2020;25(5):1039. DOI: 10.3390/molecules25051039

20. Strasenburg W., Jóźwicki J., Durślewicz J., Kuffel B., Kulczyk M.P., Kowalewski A., et al. Tumor cell-induced platelet aggregation as an emerging therapeutic target for cancer therapy. Front Oncol. 2022;12:909767. DOI: 10.3389/fonc.2022.909767

21. Arterial Thromboembolism. Res Pract Thromb Haemost. 2021;5(Suppl 2):e12589. DOI: 10.1002/rth2.12589

22. Chen Y., Zhou J., Liu Z., Wu T., Li S., Zhang Y., et al. Tumor cellinduced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment. J Exp Clin Cancer Res. 2023;42(1):277. DOI: 10.1186/s13046-023-02856-1

23. Wright J.R., Chauhan M., Shah C., Ring A., Thomas A.L., Goodall A.H., et al. The TICONC (Ticagrelor-Oncology) Study: implications of P2Y 12 inhibition for metastasis and cancer-associated thrombosis. JACC CardioOncol. 2020;2(2):236–50. DOI: 10.1016/j.jaccao.2020.04.009